Navigation Links
Patients Taking Inhaled Steroids may Develop Pneumonia

Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly being prescribed inhaled corticosteroids to control exacerbations of the disease , but a new study finds that the anti-inflammatory drugs increase the chances that these patients will be hospitalized for pneumonia.

In a large cohort of patients with COPD, we found that current inhaled corticosteroid use was associated with a significant 70 percent increase in the risk of being hospitalized for pneumonia, said the researchers.

Furthermore, for the severest pneumonias leading to death within 30 days of hospitalization, the risk with current inhaled corticosteroid use was also significantly increased.

These and other findings of the population-based study were reported in the second issue of the July American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Pierre Ernst, M.D., a clinical epidemiologist at McGill University, Canada, along with three other researchers from the universitys department of medicine, analyzed the hospitalization and drug prescription information from 1988 to 2003 of 175,906 patients with COPD living in Quebec, Canada. During that time, 23,942 of the patients were hospitalized for pneumonia.

In their report, the researchers noted that the admission rate for pneumonia increased with higher doses of inhaled steroids and that reduction in risk was observed once the medications were stopped. Among all patients taking inhaled steroids, there was a 53 percent increase in pneumonia deaths within 30 days of being admitted to the hospital.

The investigators noted that these findings are particularly relevant, given that pneumonia is the third leading cause of hospitalization in the United States and that inhaled corticosteroid use among patients with COPD increased from 13.2 to 41.4 percent from 1987 to 1995.

Adverse effects of inhaled c orticosteroids in patients with COPD, the authors said, are particularly troublesome given the limited evidence for their efficacy.

In an accompanying editorial, Mark Woodhead, D.M, of Manchester (U.K.) Royal Infirmary, wrote that this report confirms secondary findings from a prospective, placebo-controlled study of an inhaled corticosteroid with long-acting antagonist that was recently published.

Given that this earlier study was not designed to analyze pneumonia frequency, its small size and high drop-out rate, he suggested, might lead a reader to reasonably conclude that its pneumonia findings were spurious.

Now, with the addition of the Canadian population-based study, Dr. Woodhead wrote, the unexpected conclusion--that drugs prescribed to prevent COPD exacerbations put patients at greater risk for severe pneumoniadeserves further consideration and study through large prospective studies with objective pneumonia definitions.

The finding of an association, he said, between pneumonia frequency and inhaled corticosteroid use in studies of different design, in different populations, and with evidence of a dose-response relations means that the findings may be real and that these observations cannot simply be dismissed.


'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... solution that enables organizations to easily reprint customer invoices, bills, statements and other ... all of the steps needed to retrieve and print the documents and batch ...
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 — ... the new EU MDR language change the way manufacturers approach CERs? , ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... COPENHAGEN, Denmark , March 23, 2017 ... utilizes its innovative TransCon technology to address significant unmet ... company will host a conference call and webcast on ... of the Endocrine Society in Orlando, Florida ... rare disease pipeline candidates (TransCon Growth Hormone, TransCon PTH ...
(Date:3/23/2017)... 23, 2017 Prima BioMed has ... trial of IMP321 in combination with Keytruda, with one ... cohort experiencing a complete response. Recruitment in the second ... to be fully recruited by Q317. Preliminary efficacy data ... cancer study are expected mid-year (recruitment in the 226-patient ...
(Date:3/23/2017)... 2017 Piramal Pharma Solutions ... el nombramiento de Stuart E. Needleman ... servicios integrados completa para su base de clientes ... en el crecimiento y ejecución de las ofertas ... impulsar todas las actividades de desarrollo empresarial global ...
Breaking Medicine Technology: